| Journal of Clinical Medicine Research, ISSN 1918-3003 print, 1918-3011 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Clin Med Res and Elmer Press Inc |
| Journal website http://www.jocmr.org |
Review
Volume 1, Number 1, April 2009, pages 8-12
Chemotherapy Induced Cardiomyopathy: Pathogenesis, Monitoring and Management
Table
| TYPE I e.g. Doxorubicin | TYPE II e.g. Trastuzumab |
|---|---|
| Cellular death Damage starts with first administration | Cellular dysfunction |
| Biopsy changes | No typical biopsy changes |
| Cumulative dose related | Not cumulative dose related |
| Permanent damage (Myocyte death) | Predominately reversible (Myocyte dysfunction) |
| Risk factors | Risk factors |
| Prior/concurrent radiotherapy | Prior/concurrent anthracycline |
| Combination chemotherapy | Paclitaxel |
| Age | Age |
| Previous cardiac disease | Previous cardiac disease |
| Hypertension | Obesity (BMI > 25) |